Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Gennari, C
Language :
English
Title :
Paget’s disease of bone : diagnosis and management
Barker DJP, Chamberlain AT, Guyer PB, Gardner MJ. Paget's disease of bone: the Lancashire focus. BMJ 1980; 280: 1105–7.
Meunier PJ, Salson C, Mathieu L, Chapuy MC, Delmas PD, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop 1987; 217: 37–44.
Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestations of Paget's disease of bone. Am J Med 1974; 56: 592–603.
Devlin RD, Retallack RW, Fenton AJ, Grill V, Gutteridge DH, Kent GN, et al. Long term evaluation of 1,25-dihydroxyvitamin D after short term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone. J Bone Miner Res 1994; 9: 81–85.
Walton RJ, Preston CJ, Bartlett M, Smith R, Russell RG. Biochemical measurements in Paget's disease of bone. Eur J Clin Invest 1977; 7: 37–39.
Alvarez L, Guanebens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10: 458–65.
Mundy GR. Bone remodelling and its disorders. London: Martin Dunitz, 1995: 32.
Delmas PD, Demiaux B, Malaval L, Chapuy MC, Meunier PJ. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 1986; 38: 60–61.
Coulton LA, Preston CJ, Cough M, Kanis JA. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment. Arthritis Rheum 1988; 31: 1142–7.
Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127–32.
Chapman CK. The diagnosis of Paget's disease of bone. Aust NZ J Surg 1992; 62: 24–32.
Gebhardt MC, Mankin HJ. The diagnosis and management of bone tumors. In: AvioliL V, Krane SM, eds. Metabolic bone disease and clinically related disorders. Philadelphia: Saunders, 1990: 764–9.
Mautalen CA, Gonzalez D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget's disease of bone. Bone 1985; 6: 429–32.
Gray RE, Yates AJ, Preston CJ, Smith R, Russell RGG, Kanis JA. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 1987; 64: 755–67.
Harinck HI, Bijvoet OL, Blanksma H-J, Dahlinghaus Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 1987; 217: 79–98.
Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res 1993; 8: 1467–73.
Hosking DJ. Advances in the management of Paget's disease of bone. Drugs 1990; 40: 829–40.
Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz, 1991: 47–9.
Dodd GW, Ibbertson HK, Fraser TRC, Holdaway IM, Wattie D. Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol 1987; 60: 849–60.
Patel S, Pearson D, Hosking DJ. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Arthritis Rheum 1995; 38: 1506–12.
Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, et al. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 1977; 44: 96–106.
Khairi MRA, Johnston CC, Altman RD, Wellman HN, Serafinin AN, Sankey RR. Treatment of Paget's disease of bone (osteitis deformans): results of one year study with sodium etidronate. JAMA 1974; 230: 562–7.
Douglas DL, Duckworth T, Kanis JA, Jefferson AA, Martin TJ, Russell RGG. Spinal cord dysfunction in Paget's disease of bone. J Bone Joint Surg 1981; 63B: 495–503.
DeRose J, Singer F, Avramides A, Flores A, Dziandiw R, Baker RK, et al. Response of Paget's disease to porcine and salmon calcitonins. Effects of long term treatment. Am J Med 1974; 56: 858–66.
Lando M, Hoover LA, Finerman G. Stabilisation of hearing loss in Paget's disease with calcitonin and etidronate. Arch Otolaryngol Head Neck Surg 1988; 114: 891–4.
Goutallier D, Sterkers Y, Cadeau F. Experience de la prosthese totale au cours de la coxopathie pagetique. Rhumatologie 1984; 36: 81–82.
Stauffer RN, Sim FH. Total hip arthroplasty in Paget's disease of the hip. J Bone Joint Surgery 1976; 58A: 476–8.
Wooton R, Reeve J, Spellacy E, Tellez-Yudilevich M. Skeletal blood flow in Paget's disease of bone and its response to calcitonin therapy. Clin Sci Mol Med 1978; 54: 69–74.
Compston JE. The therapeutic use of bisphosphonates. BMJ 1994; 309: 711–5.
Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease. Drugs 1993; 46: 594–617.
Adami S, Mian M, Gatti P, Rossini M, Zamberlan N, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1995; 15: 415–7.
Cantrill JA, Anderson DC. Treatment of Paget's disease of bone. Clin Endocrinol 1990; 32: 507–18.
Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, et al. Comparative prospective, double blind, multicentre study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995; 38: 851–8.
